Immunity to human immunoglobulin injections lasts about 3 to 4 weeks, but may be longer or shorter depending on the individual. Injectable human immunoglobulin is used for primary immunoglobulin deficiencies such as variant immunodeficiency disease, secondary immunoglobulin deficiencies such as severe infections, neonatal sepsis, and autoimmune diseases such as primary thrombocytopenic purpura. It has been shown in the literature that sedated human immunoglobulin enters the subject’s circulation completely immediately after infusion and is rapidly distributed in plasma and extravascular body fluids. The half-life is about 3 to 4 weeks, but this half-life varies from person to person. Therefore, immunity to human immunoglobulin injections is maintained for approximately 3 to 4 weeks, but may be longer or shorter depending on the individual. Human immunoglobulin is contraindicated in selective IgA-deficient patients who are allergic to human immunoglobulin, or who have a history of other severe allergies, and who have IgA antibodies. Also, hives can occur with the use of its injectable preparations, and anaphylactic shock can occur in severe cases of cough and fever. Adverse reactions such as transient headache, panic and nausea may occur with this drug. Note that this product is intended for intravenous use and should be used up as soon as it is opened, without splitting or giving it to a second person for infusion. This medication should be taken regularly under the guidance of a doctor to avoid damage to the body caused by blind use.